Journal: Journal of Extracellular Vesicles

Article Title: RAB22A sorts epithelial growth factor receptor (EGFR) from early endosomes to recycling endosomes for microvesicles release

doi: 10.1002/jev2.12494

Figure Lengend Snippet: RAB22A increases cell‐surface EGFR expression. (a, c) Representative Western blot showing cell surface EGFR protein level on HeLa cells treated with vehicle, 25 µM Dyngo‐4a (a), or 150 µM primaquine (c). (b, d) Representative Western blot showing EGFR level on MV from HeLa cells treated with vehicle, 25 µM Dyngo‐4a (b), or 150 µM primaquine (d). (e) Representative Western blot showing EGFR level on MV from HeLa cells expressing Vector, HA‐RAB11A, HA‐RAB11A Q70L or HA‐RAB11A S25N . (f) Representative Western blot showing cell surface EGFR level on HeLa cells expressing vector or FLAG‐RAB22A. (g) Representative Western blot showing cell surface EGFR level on HeLa cells with or without RAB22A knockout. (h–j) Cell surface EGFR level in A549 (h), NCI‐H1975 (i) and NCI‐H820 (j) cell lines which was transduced with control small interfering RNA (si#NC) or siRNA targeting RAB22A (si#1 and si#2) for 48 h was analysed by flow cytometry. Data represent mean ± s.e.m.; p < 0.05 was considered significant; two‐tailed unpaired t ‐test. FLOT2 was used as a loading control.

Article Snippet: Dyngo‐4a (S7163), Primaquine (S4237), Osimertinib (S7297), WZ4002 (S1173), Erlotinib (S1023) and Lapatinib (S2111) were purchased from Selleck.

Techniques: Expressing, Western Blot, Plasmid Preparation, Knock-Out, Transduction, Control, Small Interfering RNA, Flow Cytometry, Two Tailed Test

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the OAIs, excipients and packaging used in the compounded formulations

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Capsules

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Priority list of the OAIs

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques:

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the OAIs included in current study

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Concentration Assay, Capsules

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the applied analytical methods

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Injection

Journal: Orphanet Journal of Rare Diseases

Article Title: Pharmaceutical compounding of orphan active ingredients in Belgium: how community and hospital pharmacists can address the needs of patients with rare diseases

doi: 10.1186/s13023-019-1154-x

Figure Lengend Snippet: Overview of the shelf life and assay stability results

Article Snippet: Primaquine phosphate , BOC Sciences Creative Dynamics, Shirley, United States.

Techniques: Capsules

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Effect of Fluorescent Dyes on In Vitro -Differentiated, Late-Stage Plasmodium falciparum Gametocytes

doi: 10.1128/AAC.03772-14

Figure Lengend Snippet: In vitro activities of standard antimalarial drugs and dyes against stage V gametocytes of the P. falciparum 3D7 laboratory strain and clinical isolates after 48 h of incubation a

Article Snippet: Artesunate and primaquine were from Santa Cruz Biotechnology. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 2 caption a7 Chemical structures of the tested synthetic dyes.

Techniques: In Vitro, Incubation

Journal: Antimicrobial Agents and Chemotherapy

Article Title: Effect of Fluorescent Dyes on In Vitro -Differentiated, Late-Stage Plasmodium falciparum Gametocytes

doi: 10.1128/AAC.03772-14

Figure Lengend Snippet: In vitro activities of compounds against mature gametocytes of 3D7 and clinical isolates of P. falciparum after 24 h or 48 h of incubation a

Article Snippet: Artesunate and primaquine were from Santa Cruz Biotechnology. fig ft0 fig mode=article f1 fig/graphic|fig/alternatives/graphic mode="anchored" m1 Open in a separate window FIG 2 caption a7 Chemical structures of the tested synthetic dyes.

Techniques: In Vitro, Incubation

Journal: The Journal of General Physiology

Article Title: Rapid resensitization of ASIC2a is conferred by three amino acid residues in the N terminus

doi: 10.1085/jgp.201812224

Figure Lengend Snippet: The prolonged desensitization of the ASIC2a mutants is not due to an internalization of the ion channels in response to extracellular protons. (A) Currents elicited by three consecutive applications of pH 4.0 for 20 s in HEK293T cells expressing either Mut2 (upper) or Mut3 (lower) in the absence (blue) or presence (red) of 50 µM primaquine, begun 1 h before the recordings. (B) Peak current densities in cells expressing either Mut2 (upper) or Mut3 (lower) were normalized to those evoked by the initial acidic stimulus in the absence (blue) or presence (red) of 50 µM primaquine. n = 5 for each group. Acidic stimuli were delivered by switching the bath solution from pH 7.4 to pH 4.0 at 2-min intervals. (C and D) Western blotting showing the amounts of GFP-tagged Mut2 and Mut3 in the plasma membrane (PM) and total cell lysate (Total) following application of pH 7.4 versus pH 4.0. E-cadherin and GAPDH are markers used to normalize the amounts of Mut2 and Mut3 in the plasma membrane and total cell lysate, respectively. n = 3 for each group. n.s. not significant; Mann–Whitney U test.

Article Snippet: Transfected HEK293 cells were pretreated for 1 h with primaquine (50 μM; LKT Laboratories), and the bath solution was continuously perfused with primaquine over the course of the recording.

Techniques: Expressing, Western Blot, Clinical Proteomics, Membrane, MANN-WHITNEY